Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Metastatic colorectal cancer KRAS genotyping in routine practice: results and pitfalls.

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc - 1 Aug 2011

Lamy Aude, Blanchard France, Le Pessot Florence, Sesboüé Richard, Di Fiore Frédéric, Bossut Jessie, Fiant Elodie, Frébourg Thierry, Sabourin Jean-Christophe

Abstract excerpt

KRAS genotyping is mandatory before anti-epidermal growth factor receptor monoclonal antibody therapy in metastatic colorectal cancer, which is the second leading cause of cancer-related death in the United States and in Europe. Thus, large-scale KRAS mutation screening is needed for efficient patient management and in the future metastatic colorectal cancer genotyping might also include the detection of the BRAF...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Artifacts
Share to Formaldehyde

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genotyping Techniques

Share to Neoplasm Metastasis

Share to Paraffin Embedding

Share to Proto-Oncogene Proteins p21(ras)

Share to ras Proteins

Share to Tissue Fixation

Source

Identifiers

PMID: 21516079
DOI: 10.1038/modpathol.2011.60

Genes

KRAS
BRAF

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Metastatic colorectal cancer KRAS genotyping in routine practice: results and pitfalls.PMID 21516079Read ↗

Multi-Center Evaluation of the Fully Automated PCR-Based Idylla™ KRAS Mutation Assay for Rapid KRAS Mutation Status Determination on Formalin-Fixed Paraffin-Embedded Tissue of Human Colorectal CancerSemantic proximity Read ↗

Heterogeneity of KRAS status may explain the subset of discordant KRAS status between primary and metastatic colorectal cancer.Semantic proximity Read ↗

KRAS mutation testing in metastatic colorectal cancer.Semantic proximity Read ↗

KRAS mutation testing in colorectal cancer as an example of the pathologist's role in personalized targeted therapy: a practical approach.Semantic proximity Read ↗

Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases.Semantic proximity Read ↗

Performance and Cost Efficiency of KRAS Mutation Testing for Metastatic Colorectal Cancer in Routine Diagnosis: The MOKAECM Study, a Nationwide ExperienceSemantic proximity Read ↗

Clinical performance evaluation of a sensitive, rapid low-throughput test for KRAS mutation analysis using formalin-fixed, paraffin-embedded tissue samples.Semantic proximity Read ↗

Genetic analysis of KRAS mutation status in metastatic colorectal cancer patients.Semantic proximity Read ↗

Reliability of KRAS mutation testing in metastatic colorectal cancer patients across five laboratories.Semantic proximity Read ↗

KRAS mutation testing of colorectal cancer for anti-EGFR therapy: dogmas versus evidence.Semantic proximity Read ↗

Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer.Semantic proximity Read ↗

KRAS mutations: analytical considerations.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.